Cases & Deals

  • Home
  • Practices
  • REGENXBIO successfully blocks institution of post-grant review of gene therapy patent

Share

REGENXBIO successfully blocks institution of post-grant review of gene therapy patent

October 2021

Client(s) REGENXBIO Inc.

Jones Day successfully defended REGENXBIO, Inc. against a post-grant review (PGR) petition filed by Passage Bio before the U.S. Patent Trial and Appeal Board (PTAB) against one of REGENXBIO's AAV9 patents. The PTAB denied institution of the review.

Passage Bio, Inc. v. Trustees of the University of Pennsylvania et al., PGR2021-00073 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.